The demand for decentralized testing is increasing due to rising incidences of infectious diseases in developing countries. The increasing usage of decentralized testing and technological innovations with respect to ease of use and faster testing devices are encouraging the usage of decentralized testing. The decentralized testing market has professional and patient friendly or self-monitored testing like food pathogens, hematology, infectious diseases, coagulation test and urine analysis. Rapid results and first hand treatment reduces the downstream costs. As the conventional health care sector shifts to modern health care, more services can be presented to the patients at the decentralized testing of the patient.
The factors driving the trend of decentralized infectious disease testing include increasing trend of patient centric care, technological innovations, shortage of laboratory staff, increasing aging population, and rising incidences of infectious diseases. Even the diagnostic laboratories are also transforming on the basis of this format, where complex tests are performed in core labs and decentralized testing is performed in clinics, outpatient clinics or at patients home. This improves quality of care and access of care to the geriatric population. Advancements in the technology have been made such that it can be performed even by moderately trained staff. Many tests require labs for testing but now can be performed at the point of care. Another factor which drives the decentralized infectious disease testing market is the lack of trained staff in the laboratories. With less trained laboratory staff, drives the labs towards automated testing procedures and towards minimal user interaction systems. Thus, factors such as reduced sample volume, less specimen processing, shorter hospital stay, optimized medicine treatment and less post-operative care time support the growth of decentralized infectious disease testing market.
Request a Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14177
The decentralized infectious disease testing gives results for over 75 type of infectious diseases across varied testing platforms which include advanced technology laboratory equipment along with rapid diagnostic tests that can provide results for individual patients in less than or equal to 5 minutes. Infectious diseases such as malaria, measles, mumps, rubella, herpes simplex virus, cytomegalovirus, dengue fever, HIV and many more, can be detected through decentralized infectious disease testing procedures.
Briefly, North America has more options and a bigger share in the decentralized infectious disease testing market followed by Europe. With improved infrastructure and increasing awareness the global decentralized infectious disease testing market will have a boost in emerging countries of Asia Pacific. The prominent players having presence in the global decentralized infectious disease testing market are Becton-Dickinson and Company, Abbott Laboratories, Beckman Coulter, Inc., Siemens Medical Solutions, Nipro Diagnostics and Johnson & Johnson.